Affiliation:
1. University of Southern California Keck School of Medicine
2. University of California Los Angeles Health System: UCLA Health
3. University of Southern California School of Pharmacy
Abstract
Abstract
Background
Early evidence-based medical interventions to improve patient outcomes after traumatic brain injury (TBI) are lacking. In patients admitted to the ICU after TBI, optimization of nutrition is an emerging field of interest. Specialized enteral nutrition (EN) formulas that include immunonutrition containing omega-3 polyunsaturated fatty acids (n-3 PUFAs) have been developed and are used for their proposed anti-inflammatory and pro-immune properties; however, their use has not been rigorously studied in human TBI populations.
Methods
A single-center, retrospective, descriptive observational study was conducted at LAC + USC Medical Center. Patients with severe TBI (sTBI, Glasgow Coma Scale score ≤ 8) who remained in the ICU for ≥ 2 weeks and received EN were identified between 2017 and 2022 using the institutional trauma registry. Those who received immunonutrition formulas containing n-3 PUFAs were compared to those who received standard, polymeric EN in regard to baseline characteristics, clinical markers of inflammation and immune function, and short-term clinical outcomes.
Results
A total of 151 patients with sTBI were analyzed. Those who received immunonutrition with n-3 PUFA supplementation were more likely to be male, younger, Hispanic/Latinx, and have polytrauma needing non-central nervous system surgery. No differences in clinical markers of inflammation or infection rate were found. In multivariate regression analysis, immunonutrition was associated with reduced hospital length of stay (LOS). ICU LOS was also reduced in the subgroup of patients with polytrauma and TBI.
Conclusion
This study identifies important differences in patient characteristics and outcomes associated with the EN formula prescribed. Study results can directly inform a prospective pragmatic study of immunonutrition with n-3 PUFA supplementation aimed to confirm the biomechanistic and clinical benefits of the intervention.
Publisher
Research Square Platform LLC
Reference37 articles.
1. Centers for Disease Control and Prevention. National Center for Health Statistics. : Mortality data on CDC WONDER. Available at: https://wonder.cdc.gov/mcd.html. Accessed August 14, 2023.
2. Zaloshnja E, Miller T, Langlois JA, Selassie AW. Prevalence of long-term disability from traumatic brain injury in the civilian population of the United States, 2005. J Head Trauma Rehabil. 2008 Nov-Dec;23(6):394–400. 10.1097/01.HTR.0000341435.52004.ac. PMID: 19033832.
3. Carney N, Totten AM, O'Reilly C et al. Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition. Neurosurgery. 2017;80(1):6–15. 10.1227/NEU.0000000000001432. PMID: 27654000.
4. Kuo GY, Tarzi F, Louie S, Poblete R. Neuroinflammation in Traumatic Brain Injury. 2002. IntechOpen. 10.5772/intechopen.105178.
5. Nutrition therapy and critical illness: practical guidance for the ICU, post-ICU, and long-term convalescence phases;Zanten ARH;Crit Care,2019